ultiple sclerosis (MS) is a chronic inflammatory and demyelinating disease of the central nervous system (CNS) associated with autoaggressive T and B cell responses to various myelin proteins. Myelin oligodendrocyte glycoprotein (MOG) was identified as a candidate autoantigen in MS because it induces a demyelinating antibody response in laboratory animals with experimental autoimmune encephalomyelitis (EAE), an animal model of MS (1). MOG is a quantitatively minor type I transmembrane CNS protein of unknown function with a single extracellular Ig-like domain (2). In contrast to other CNS proteins, MOG is found only in mammals and is highly conserved across species. It is expressed exclusively in the CNS by myelin-forming oligodendrocytes and is preferentially localized at the outermost surface of the myelin sheath thus directly exposed to autoantibodies in the extracellular milieu. MOG is the only antigen that can induce both a pathogenic demyelinating autoantibody response and an encephalitogenic T cell response in experimental animals (3). In MOG-induced EAE this combination of immune effector mechanisms reproduces the demyelinating pathology seen in the majority of patients with MS. The clinical relevance of autoimmune responses to MOG in MS is supported by reports that MS is associated with enhanced MOG-specific T and B cell responses and by the identification of MOG-specific antibodies associated with myelin debris in actively demyelinating MS lesions (4). Experimental evidence indicates that the autoantibody response to MOG is heterogeneous; demyelinating MOG-specific autoantibodies recognize purely conformation-dependent epitopes whereas MOG peptide-specific antibodies fail to recognize the native protein (5-7). To examine the structural basis of the pathogenic autoantibody response to MOG we determined the crystal structures of the extracellular domain of rat MOG (residues 1-126, MOG Igd ) and a complex of MOG Igd with the chimeric antigen-binding fragment (Fab) of the demyelinating MOG-specific monoclonal antibody 8-18C5 (8).
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Materials and Methods

Preparation of Recombinant MOG Igd and the MOG Igd -(8-18C5)-Fab
Complex. The cDNA of the extracellular domain of rat MOG (residues 1-125) was subcloned into the His-tag expression vector pQE-12. The protein was overexpressed in inclusion bodies in Escherichia coli, refolded, and further purified by nickel-nitrilotriacetic acid affinity chromatography and gel filtration. Selenomethionine (SeMet)-labeled protein was produced in the methionine-auxotrophic E. coli strain B834(DE3) and grown in minimal medium with SeMet (0.3 mM) substituted for methionine. The cDNA of the variable domains of the mouse monoclonal antibody 8-18C5 was subcloned into the expression vector pASK107, yielding the chimeric (8-18C5)-Fab composed of the 8-18C5 variable domains, the human IgG constant domains, and the Strep tag II fused to the C terminus of the heavy chain (9, 10) . (8-18C5)-Fab was produced by periplasmic secretion in E. coli and purified by streptavidin affinity chromatography and gel filtration (11) . A 1:1 molar ratio of MOG Igd and (8-18C5)-Fab was mixed to form the MOG Igd -(8-18C5)-Fab complex followed by a final gel-filtration chromatography step.
Crystallization and Data Collection. Crystals were grown at 18°C with the sitting drop vapor diffusion method by mixing 2 l of 5 mg͞ml MOG Igd or SeMet-MOG Igd solution (10 mM Tris⅐HCl, pH 7.4͞30 mM NaCl) with 1 l of reservoir solution (100 mM Tris⅐HCl, pH 7.2͞100 mM MgAc 2 ͞22% polyethylene glycol 8000) and equilibrating against reservoir solution. The complex was crystallized by combining 2 l of 3. , and the complex ( ϭ 1.0500 Å) as well as multiple anomalous diffraction data of SeMet-MOG Igd ( 1 ϭ 0.9791 Å, 2 ϭ 0.9795 Å, and 3 ϭ 0.9500 Å) were collected at beamline BW6 at the German Electron Synchrotron (Hamburg, Germany). Data sets were integrated, scaled, and merged by using DENZO (13) , and parameters were refined and phases calculated with MLPHARE (14) . The resulting electron density at 1.9-Å resolution, improved by density modification carried out by using DM (14) , enabled building of nearly the complete model of SeMet-MOG Igd . Refinement of the model in CNS (15) and manual rebuilding in O (16) was performed by using a high-resolution data set of SeMet-MOG Igd (1.45-Å resolution). The final model comprises 124 residues and has R values of R ϭ 19.5%͞R free ϭ 21.9%. The structure of native MOG Igd determined by molecular replacement and refined against a data set of 2.2-Å resolution showed no significant differences compared with the high-resolution structure of SeMet-MOG Igd that was therefore used for subsequent structural analysis.
The (20) . Fixing the two constant domains during translation search yielded the position of the constant domains of the second molecule with the noncrystallographic symmetry axis parallel to the cell axis a and ϭ 40°, consistent with the solution of the self-rotation function. Subsequently, the positions of all constant domains were fixed for input into the likelihood-based molecular replacement program BEAST (21) , which yielded correct solutions of the variable domains and MOG Igd of one protomer. The remaining domains were clearly visible in the resulting electron-density map. Refinement in CNS was performed with restrained noncrystallographic symmetry imposed on the individual Ig domains excluding N and C termini and the hinge regions of heavy and light chains. Averaged
SigmaA-weighted and composite-omit (2F o Ϫ F c ) maps were used for manual rebuilding in O. During refinement, R values dropped from R ϭ 40.6%͞R free ϭ 41.3% to R ϭ 25.0%͞R free ϭ 31.8%, yielding the final model that comprises 561 residues. Calculation of atomic contacts and solvent-accessible surfaces was performed with the CCP4 package (14) , searches for related sequences were done with BLAST (24) , GRASP (25), and ALSCRIPT (26).
Results and Discussion
Overall Structure of MOG Igd . MOG Igd adopts a classical IgV-like fold consisting of a sandwich of two antiparallel ␤-sheets that comprise strands AЈGFCCЈCЉ and ABED, respectively ( Fig. 1 a  and b) . The glycosylation site of MOG, Asn-31, is located in the loop connecting the B and C strands (BC loop), exposed at the top, membrane-distal side of MOG Igd . MOG Igd is monomeric in the crystal and exhibits a predominantly polar surface that lacks any large hydrophobic or positively charged patches, suggesting that MOG Igd does not interact directly with the phospholipid membrane. The main protein-protein contacts formed by MOG Igd in the densely packed crystal are nonphysiological interactions of the C-terminal tail (residues 116-126) with crystallographic neighbors. Because of those stabilizing interactions the C terminus is visible in the electron density with the last ordered residue, Val-126, corresponding to the first residue of the predicted membrane-spanning helix. MOG is structurally similar to other IgV domains such as the peripheral nerve system protein P zero (27) , the IgV domains of the ␥␦-T cell receptor (28) , and various variable antibody domains. The nearest structural neighbors of MOG are the N-terminal domains of the costimulatory molecule B7-2 (29) (CD86) and sialoadhesin (30) , which superimpose with MOG with rms deviations of 1.18 and 1.37 Å for 97 and 100 aligned C ␣ atoms, respectively.
Functional Implications. Despite its important role as target antigen in EAE and MS, the physiological function of MOG is unknown. It has been suggested that MOG acts as an adhesion or signaling molecule or as an activator of the complement cascade by binding the complement component C1q (2) . Intriguingly, B7-2 and MOG both exhibit a very short CЉ strand and share the twisted conformation of the CЉD loop, which constitutes one edge of a shallow cavity built by the AЈGFCCЈCЉ sheet (Fig. 1c) . In B7-2 this cavity is utilized to bind CTLA4 (29) . The IgV domains of B7-2 and MOG that are both encoded within the MHC show sequence identities of 27%, but the amino acids that contribute to the formation of the cavity are not conserved between MOG and B7-2. Despite this lack of conservation, the cavities of both molecules exhibit a similar hydrophobic center enclosed by polar residues, suggesting that this region of MOG Igd may act as a binding site for an as-yet-unidentified ligand. The C1q-binding site of mouse IgG2 has been mapped to the sequence EXKXK, located in the F strand of the second constant Ig domain of the IgG2 heavy chain (31) . A similar sequence can be identified in the Ig domain of MOG (E 64 YRGR 68 ), and it has been demonstrated that MOG binds C1q, leading to activation of complement in vitro (32) . The structure of MOG Igd reveals that the proposed C1q complement-binding site is orientated toward the membrane surface and forms two antiparallel tight turns (Fig. 1c) , adopting a conformation that differs completely from the extended conformation of the original C1q-activating sequence in IgG2, indicating that complement activation is not the normal physiological function of MOG.
Antigenicity of MOG Igd . The three-dimensional structure of MOG Igd allows us to identify solvent-exposed surfaces that may provide targets for autoantibody-mediated demyelination (Fig.  1b) . The specificity of anti-MOG autoantibodies with demyelinating activity is strongly biased toward conformationdependent epitopes, but the regions of MOG that support this response are unknown. One exception is a minor subset of conformation-dependent murine monoclonal antibodies that bind MOG as well as peptides containing amino acids 63-87 (7). This sequence encompasses the DE loop (amino acids 72-80), which contains highly exposed residues and forms part of a protruding surface at the top of the BED sheet, consistent with forming a minor, partially sequential epitope (Fig. 1d) . In addition, Lewis rats immunized with the MOG peptide (amino acids 35-55) develop a demyelinating variant of EAE that led to the assumption that this sequence contains a pathogenic B cell epitope (33) . Because of the concave surface of the AЈGFCCЈCЉ sheet, the C and CЈ strands are largely buried ( Fig. 1 b and d) , whereas the protruding CCЈ loop (amino acids 41-46) is surfaceexposed and highly flexible in the crystal structure, and thus available to bind antibodies. , which is in the normal range for antibody-protein interactions (36) , with the dominant contribution being made by the heavy chain of 8-18C5 (Fig. 2 a  and b) . This is consistent with the observation that in mice transgenic for the heavy chain of 8-18C5 MOG binding is maintained by pairing this heavy chain with different endogenous light chains (37) .
Interactions of the light chain with MOG
Igd are restricted to the complementarity-determining region 1 (CDR1) and to the CDR3 residues 92-94. The former binds the BC and the CЈCЉ loops via interactions with the MOG residues Thr-33, Gly-34, Asn-53, and Gly-54 (Fig. 2c) . In addition, Asn-53 forms two hydrogen bonds to Fab light-chain residues. CDR1 and CDR3 of the 8-18C5 light chain are identical to the corresponding regions of their germ-line sequence (IgV 8-28); a remarkable feature of CDR1, however, is its length of 17 residues, the maximum observed for V-CDR1 sequences (38) , which enables CDR1 to form contacts to MOG residues distant from the center of the binding site.
The major interaction site of MOG Igd and 8-18C5 is formed by the three CDRs of the heavy chain and residues of the G strand of 
MOG
Igd and the preceding FG loop (amino acids 101-108) that account for 65% of the total interaction surface of MOG Igd . By binding to 8-18C5, the FG loop of MOG becomes completely buried in a cavity formed by the three heavy-chain CDRs (H1-H3) and Tyr-32 and Tyr-94 of the light chain (Fig. 2d) . Asp-102, His-103, and Ser-104 occupy the bottom of this cavity and form numerous hydrophobic and polar interactions with H3. The MOG residues Ser-104 and Gln-106 are fixed by main-chain hydrogen bonds to H1 (Ser-31 and Trp-33), thus establishing a short intermolecular ␤-sheet. Strong hydrogen bonds are formed between the side chains of Glu-107 and Glu-108 and of the non-germ-line H2 residues Arg-54 and Arg-56, respectively, as well as between residues of the FG loop and the surrounding CDRs (Fig. 2d) . The highly specific binding of the sequence 101-108 is further supported by van der Waals interactions of several MOG residues with the Fab heavy chain in the periphery of the binding site (Fig. 2b) . Compared with the structure of uncomplexed MOG Igd , the FG loop of MOG Igd is slightly displaced after antibody binding, and several MOG Igd side chains are repositioned to enable optimal binding to 8-18C5 residues (Fig. 3a) .
MOG Interface Residues 101-108. While it was anticipated that the MOG epitope recognized by 8-18C5 would be highly discontinuous (Fig. 3b) , the dominant role of the sequence 101-108 that comprises the FG loop is surprising. The FG loop that protrudes from the top of the Ig domain forms a hairpin loop classified as a IIЈ ␤-turn. The second position of IIЈ ␤-turns is normally a glycine (39) in MOG Igd ; however, it is occupied by His-103, which results in a strained loop conformation with dihedral angles of His-103 in forbidden regions of the Ramachandran plot. This provides a simple explanation for the failure to detect this antigenic region by peptide mapping with linear peptides that are unable to reproduce this strained loop structure.
Residues with strained conformations are often positioned at functionally important sites in proteins. Intriguingly, the FG loop forms the upper boundary of the B7-2-like cavity described above, supporting the idea that this cavity is involved in binding a ligand (Fig. 3b) . This putative interaction would be perturbed when 8-18C5 binds to MOG. Interestingly, binding of 8-18C5 to MOG on the surface of oligodendrocytes leads to microtubule depolymerization in vitro, suggesting a role of MOG in the organization of the cytoskeleton that is compromised by binding of 8-18C5 (40) .
The identification of the MOG epitope recognized by 8-18C5 provides a structural basis to investigate genetic and environmental factors that may influence the MOG-specific antibody response in vivo. MOG is expressed within the immunologically privileged environment of the CNS where it is sequestered from normal lymphocyte trafficking and unable to trigger antigen-specific B cell tolerance. The composition of the anti-MOG B cell repertoire, however, can be influenced by other self-antigens (37) , which may include homologous proteins such as butyrophilin (41) or erythroid membrane-associated protein (42) , the N-terminal IgV-like domains of which exhibit sequence identities to MOG Igd of 45-55% (43) . Strikingly, those residues bound by 8-18C5, an antibody that has escaped this tolerogenic influence, are least conserved between MOG and its relatives (Fig. 1b) .
Sequence differences between MOG Igd and its homologues are most pronounced within the sequence R 101 DHSYQEE 108 , indicating that tolerance to this region of MOG will be poorly developed. In this case, molecular mimicry involving related sequences derived from microbial pathogens may trigger a pathogenic antibody response to this region of MOG. Intriguingly, a BLAST search for sequences similar to R 101 DHSYQEE 108 identified several amino sequences in proteins from Chlamydia sp., a microorganism previously associated with MS (44, 45) . The first hit of the similarity search was the sequence D 253 HSYQEE 259 in an uncharacterized protein, CT863, from Chlamydia trachomatis. This sequence is located in a region that lacks recognizable structural motifs and is predicted to be solvent-exposed and to adopt a coiled conformation raising the possibility that these residues can adopt a turn-like structure similar to that seen in MOG Igd . CT863 is also present in the genome of Chlamydia pneumonia, the Chlamydia species specifically associated with MS, but genomic sequencing suggests that this particular amino acid sequence is not conserved between species. However, the BLAST search revealed a second, moredistantly related sequence, E 379 HSYQEQ 385 , in the C. pneumonia protein CT768. Based on these structural and sequence correlations, further studies are required to determine whether immunity to C. pneumonia can trigger a potentially pathogenic antibody response to MOG.
Overall, our data provide a structural basis for understanding the pathogenic autoantibody response to MOG. The solution of the three-dimensional structure of MOG and the identification of the FG loop as a dominant component of the epitope recognized by 8-18C5 provide a starting point for the development of diagnostic and therapeutic strategies targeting MOG in MS.
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